Scientists create a 'Library' of samples to unlock mysteries of early psychosis
NCT ID NCT05340348
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create a 'patient library' by collecting blood, stool, and hair samples from 250 people aged 15 to 30 who have had a first psychotic episode or are at high risk. Researchers will track their mental health over 10 years using the CAARMS test. The goal is to better understand how psychosis develops and to identify markers that could predict who will get worse.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this library could help researchers better understand early psychosis and identify who is at risk of developing schizophrenia.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants and may take years to yield useful insights.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2022
- Expected to finish
-
Jul 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
15 to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Major and or minor aged 15 to 30 assessed within the CEVUP (Consultation for the Assessment of Psychological Vulnerability) and cared for at the psychiatry center as part of a first psychotic episode (Diagnosis CIM 10: F20 -F29 first hospitalization). These patients are referred by care and medico-social partners (general practitioners, school doctors, school nurses, educators, addictologists, psychiatrists * "At risk" status for psychotic disorder (GRD, APS, BLIPS group) or psychosis threshold during the CAARMS test (psychometric scale for the assessment of psychotic symptoms) * Consent of the patient or his legal guardian Exclusion Criteria: * History of psychosis for more than one year * "Not at risk" status for psychotic disorder on the CAARMS (psychometric scale for the assessment of psychotic symptomatology) * IQ\<70 (WAIS) * Neurological disorder or other health problem that may explain the disorders * Refusal to participate - History of psychosis for more than one year
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Chu Brest
RECRUITINGBrest, 29609, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia